Stem definition | Drug id | CAS RN |
---|---|---|
antibiotics, 6-aminopenicillanic acid derivatives | 2006 | 66-79-5 |
Dose | Unit | Route |
---|---|---|
2 | g | O |
2 | g | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 46 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 249.10 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
BA (Bioavailability) | 33 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
Vd (Volume of distribution) | 0.19 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 6.30 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.07 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 0.70 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
April 8, 1971 | FDA | SANDOZ |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug reaction with eosinophilia and systemic symptoms | 91.14 | 42.29 | 27 | 632 | 33809 | 63454554 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug reaction with eosinophilia and systemic symptoms | 57.06 | 37.57 | 26 | 1164 | 32986 | 34922755 |
Acute kidney injury | 46.24 | 37.57 | 54 | 1136 | 304934 | 34650807 |
Toxic skin eruption | 40.32 | 37.57 | 15 | 1175 | 11370 | 34944371 |
Renal tubular necrosis | 39.04 | 37.57 | 16 | 1174 | 15664 | 34940077 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Drug reaction with eosinophilia and systemic symptoms | 134.62 | 34.36 | 51 | 1682 | 64193 | 79678462 |
Eosinophilia | 73.71 | 34.36 | 30 | 1703 | 45315 | 79697340 |
Acute kidney injury | 71.90 | 34.36 | 71 | 1662 | 519333 | 79223322 |
Toxic skin eruption | 40.51 | 34.36 | 16 | 1717 | 22277 | 79720378 |
Renal tubular necrosis | 38.71 | 34.36 | 16 | 1717 | 25023 | 79717632 |
Device related infection | 36.98 | 34.36 | 17 | 1716 | 34277 | 79708378 |
None
Source | Code | Description |
---|---|---|
ATC | J01CF04 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE BETA-LACTAM ANTIBACTERIALS, PENICILLINS Beta-lactamase resistant penicillins |
FDA CS | M0016152 | Penicillins |
FDA EPC | N0000175497 | Penicillin-class Antibacterial |
MeSH PA | D000900 | Anti-Bacterial Agents |
MeSH PA | D000890 | Anti-Infective Agents |
CHEBI has role | CHEBI:33282 | bactericides |
CHEBI has role | CHEBI:36047 | antibacterial drugs |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Staphylococcal meningitis | indication | 12166008 | |
Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
Staphylococcal pneumonia | indication | 22754005 | |
Sinusitis | indication | 36971009 | |
Lower respiratory tract infection | indication | 50417007 | |
Staphylococcal infectious disease | indication | 56038003 | |
Staphylococcal endocarditis | indication | 73028002 | |
Acute bacterial sinusitis | indication | 75498004 | |
Infection of bone | indication | 111253001 | |
Staphylococcal septicemia | indication | 111821004 | |
Pharyngitis | indication | 405737000 | DOID:2275 |
Infection due to Staphylococcus aureus | indication | 406602003 | |
Osteomyelitis due to Staphylococcus aureus | indication | 428783003 | |
Sepsis due to Staphylococcus aureus | indication | 448417001 | |
Staphylococcus Epidermidis Urinary Tract Infection | indication | ||
Staphylococcus Aureus Joint Infection | indication | ||
Staphylococcus Aureus Urinary Tract Infection | indication | ||
Continuation Therapy for Chronic Osteomyelitis | indication | ||
Staphylococcal Prosthetic Heart Valve Endocarditis | indication | ||
Staphylococcus Aureus Bronchitis | indication | ||
Continuation Therapy for Acute Osteomyelitis | indication | ||
Pyrexia of unknown origin | off-label use | 7520000 | |
Cholangitis | off-label use | 82403002 | DOID:9446 |
Bacterial endocarditis | off-label use | 301183007 | |
Diabetic Foot Infection Due to Gram-Positive Bacteria | off-label use | ||
Kidney disease | contraindication | 90708001 | DOID:557 |
Infectious mononucleosis | contraindication | 271558008 | DOID:8568 |
Pseudomembranous enterocolitis | contraindication | 397683000 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 2.76 | acidic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Prostaglandin G/H synthase 2 | Enzyme | IC50 | 5.85 | WOMBAT-PK | |||||
Prostaglandin G/H synthase 1 | Enzyme | IC50 | 7.02 | WOMBAT-PK | |||||
Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A | Enzyme | IC50 | 5.04 | WOMBAT-PK | |||||
Penicillin-binding protein | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
Penicillin-binding protein 1A | Enzyme | WOMBAT-PK |
ID | Source |
---|---|
4019867 | VUID |
N0000147953 | NUI |
D00929 | KEGG_DRUG |
7240-38-2 | SECONDARY_CAS_RN |
4018149 | VANDF |
4019867 | VANDF |
C0029983 | UMLSCUI |
CHEBI:7809 | CHEBI |
CHEMBL819 | ChEMBL_ID |
CHEMBL3989567 | ChEMBL_ID |
CHEMBL693 | ChEMBL_ID |
D010068 | MESH_DESCRIPTOR_UI |
DB00713 | DRUGBANK_ID |
6196 | PUBCHEM_CID |
10943 | IUPHAR_LIGAND_ID |
1372 | INN_ID |
UH95VD7V76 | UNII |
7773 | RXNORM |
4479 | MMSL |
5207 | MMSL |
d00115 | MMSL |
002690 | NDDF |
004834 | NDDF |
372868007 | SNOMEDCT_US |
83201006 | SNOMEDCT_US |
85724000 | SNOMEDCT_US |
0WO | PDB_CHEM_ID |
1S6 | PDB_CHEM_ID |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
OXACILLIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-1013 | INJECTION, SOLUTION | 1 g | INTRAVENOUS | NDA | 24 sections |
OXACILLIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-1013 | INJECTION, SOLUTION | 1 g | INTRAVENOUS | NDA | 24 sections |
OXACILLIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-1015 | INJECTION, SOLUTION | 2 g | INTRAVENOUS | NDA | 24 sections |
OXACILLIN | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0338-1015 | INJECTION, SOLUTION | 2 g | INTRAVENOUS | NDA | 24 sections |
Oxacillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 22607-698 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 21 sections |
Oxacillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 22607-699 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 21 sections |
Oxacillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-146 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAVENOUS | ANDA | 24 sections |
Oxacillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-162 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 24 sections |
Oxacillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-162 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAVENOUS | ANDA | 24 sections |
Oxacillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-163 | INJECTION, POWDER, FOR SOLUTION | 10 g | INTRAVENOUS | ANDA | 24 sections |
Oxacillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 25021-163 | INJECTION, POWDER, FOR SOLUTION | 10 g | INTRAVENOUS | ANDA | 24 sections |
Oxacillin | Human Prescription Drug Label | 1 | 55150-127 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 22 sections |
Oxacillin | Human Prescription Drug Label | 1 | 55150-127 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 22 sections |
Oxacillin | Human Prescription Drug Label | 1 | 55150-127 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 22 sections |
Oxacillin | Human Prescription Drug Label | 1 | 55150-127 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 22 sections |
Oxacillin | Human Prescription Drug Label | 1 | 55150-128 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 22 sections |
Oxacillin | Human Prescription Drug Label | 1 | 55150-128 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 22 sections |
Oxacillin | Human Prescription Drug Label | 1 | 55150-128 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 22 sections |
Oxacillin | Human Prescription Drug Label | 1 | 55150-128 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 22 sections |
Oxacillin | Human Prescription Drug Label | 1 | 55150-129 | POWDER, FOR SOLUTION | 10 g | INTRAVENOUS | ANDA | 22 sections |
Oxacillin | Human Prescription Drug Label | 1 | 55150-129 | POWDER, FOR SOLUTION | 10 g | INTRAVENOUS | ANDA | 22 sections |
Oxacillin | Human Prescription Drug Label | 1 | 55150-129 | POWDER, FOR SOLUTION | 10 g | INTRAVENOUS | ANDA | 22 sections |
Oxacillin | Human Prescription Drug Label | 1 | 55150-129 | POWDER, FOR SOLUTION | 10 g | INTRAVENOUS | ANDA | 22 sections |
Oxacillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-811 | INJECTION, POWDER, FOR SOLUTION | 10 g | INTRAVENOUS | ANDA | 23 sections |
Oxacillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-812 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 12 sections |
Oxacillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-813 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 12 sections |
Oxacillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64679-698 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 20 sections |
Oxacillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64679-699 | INJECTION, POWDER, FOR SOLUTION | 2 g | INTRAMUSCULAR | ANDA | 20 sections |
Oxacillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 64679-700 | INJECTION, POWDER, FOR SOLUTION | 10 g | INTRAVENOUS | ANDA | 19 sections |
Oxacillin | HUMAN PRESCRIPTION DRUG LABEL | 1 | 66794-225 | INJECTION, POWDER, FOR SOLUTION | 1 g | INTRAMUSCULAR | ANDA | 11 sections |